Business   

EU offers big scope for biopharma cos.

Special Correspondent

Romania, Bulgaria can be good manufacturing bases

BANGALORE: There are enough opportunities waiting overseas for start-up Indian biopharma companies through venture capital funding, outlicensing or joint research leading to marketing in Western markets. India could have a significant cost advantage, if the companies carefully studied the global market with its constant changes and the target users.

Speaking at the session on Finance and Marketing at the Bangalore Bio here on Friday, Mark Ravera, President, Strategic Pharma Consulting Group LLC of the U.S., said Indian biotech and pharma companies need to be flexible and adaptable enough.

Crispin Kirkman, Managing Director of Emerging Technologies Network Agency, U.K., said, "Access may be uniform throughout the EU, but regional economies still differ from each other. Countries such as Romania or Bulgaria could be good manufacturing bases for Indian companies, compared to the U.K. or Germany."

Amanda Caples, Department of Innovation, Industry and Regional Development of Victoria, Australia, said her State's vision to make Melbourne one of the top five biotech locations of the world by 2010, presented immense opportunities for Indian companies to find Australian partners with access to research in that country.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Rupee futures cross $23 m on Dubai Exchange
Getting the most out of finishing schools
Panel report on gas pricing
IBM launches `Project Green'
Inflation dips below 5 p.c.
EU offers big scope for biopharma cos.
Further drop in Sensex
Exchange rates
Bullion rates
FDI policy on debentures
Activity-wise data collection
IDBI plans to raise $1.5 b
Biocon signs MoU with Deakin University
Easun Reyrolle's net up 35 p.c.
ED appointments in public sector banks
Sical Logistics wins O&M contract from ONGC
Mayfield Fund expands India operations

Copyright © 2007, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu